Fox News | April 19th, 2012

A combination of experimental hepatitis C drugs from Gilead Sciences Inc and Bristol-Myers Squibb Co showed impressive results in new clinical trial data released on Thursday, helping fuel an 11 percent rise in Gilead shares.

Gilead’s GS-7977, acquired with its $11 billion purchase of Pharmasset, when combined with Bristol’s daclatasvir led to a 100 percent response rate in previously untreated patients with the most common form of hepatitis C, according to interim data from a mid-stage trial presented at a liver disease meeting in Europe.

The results were accomplished without interferon, an injected drug that causes flu-like symptoms and other side effects that often lead patients to discontinue or delay treatment, or ribavirin, an older antiviral drug that is also currently part of all treatment regimens.

Read more: Gilead, Bristol hepatitis C drugs show promise in clinical trial